Wire · opportunities
A Breakthrough Pancreatic Drug is also Showing Results in Treating Lung Cancer
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 8 September 2026 · Fusion42 review
The drug daraxonrasib, initially approved for pancreatic cancer, shows promising early results in treating non-small cell lung cancer patients with various RAS mutations, broadening potential targeted therapy options. A phase III trial is ongoing for possible FDA approval for lung cancer treatment.
This Wire brief sits within Fusion42's coverage of Biotech, and 48 sources have reported it between 26 Aug 2026 and 24 Oct 2026.
◆ ◆ The Wire takeaway
You need to prioritise developing broader targeted therapies beyond single mutation types now because daraxonrasib shows multi-RAS inhibitor benefits in lung cancer. The expanding trial activity opens an entry point for specialised cancer treatment companies beyond pancreatic cancer.
◆ Coverage
48 sources · first reported 26 Aug 2026 · latest 24 Oct 2026
◆ Related on Wire
◆ Topics